tiprankstipranks
Nymox Pharmaceutical (NYMXF)
OTHER OTC:NYMXF
US Market
Holding NYMXF?
Track your performance easily

Nymox Pharmaceutical (NYMXF) Income Statement

141 Followers

Nymox Pharmaceutical Income Statement

Last quarter (Q ), Nymox Pharmaceutical's total revenue was $―, a decrease of ― from the same quarter last year. In Q, Nymox Pharmaceutical's net income was $―. See Nymox Pharmaceutical’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
---$ 5.00K$ 116.00K$ 299.00K
Cost of Revenue
---$ 4.00K$ 58.00K$ 138.00K
Gross Profit
---$ 1.00K$ 58.00K$ 161.00K
Operating Expense
$ 8.33M$ 6.62M$ 12.48M$ 11.72M$ 13.40M$ 10.80M
Operating Income
$ -8.33M$ -6.62M$ -12.48M$ -11.72M$ -13.34M$ -10.64M
Net Non Operating Interest Income Expense
$ -23.00K$ 6.00K$ 6.00K$ 24.00K$ 201.00K$ 101.00K
Other Income Expense
$ 3.12M$ 6.45M$ 12.52M$ 42.00K$ 13.16M$ -83.00K
Pretax Income
$ -5.24M$ -13.07M$ -25.00M$ -23.48M$ -26.30M$ -10.56M
Tax Provision
------
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -5.24M$ -13.07M$ -25.00M$ -23.48M$ -26.32M$ -10.56M
Basic EPS
$ -0.07$ -0.07$ -0.15$ -0.16$ -0.19$ -0.18
Diluted EPS
$ -0.07$ -0.07$ -0.15$ -0.16$ -0.19$ -0.18
Basic Average Shares
$ 267.71M$ 89.38M$ 81.98M$ 73.82M$ 68.84M$ 60.47M
Diluted Average Shares
$ 282.73M$ 89.38M$ 81.98M$ 73.82M$ 68.84M$ 60.47M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
$ 6.00K-----
Total Expenses
$ 8.33M$ 6.62M$ 12.48M$ 11.72M$ 13.46M$ 10.94M
Net Income From Continuing And Discontinued Operation
$ -5.24M$ -13.07M$ -25.00M$ -23.48M$ -26.32M$ -10.56M
Normalized Income
$ -5.24M-----
Interest Expense
$ 12.00K-----
EBIT
$ -8.33M$ -13.09M$ -25.02M$ -11.76M$ -26.32M$ -10.54M
EBITDA
$ -8.14M$ -12.85M$ -24.76M$ -11.75M$ -26.31M$ -10.54M
Currency in USD

Nymox Pharmaceutical Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis